Boston Chronic Kidney Disease Research Biopsy Center

波士顿慢性肾脏病研究活检中心

• 批准号: 10493645
• 负责人: Sylvia E Rosas
• 金额: $ 54.95万
• 依托单位: BOSTON MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-15 至 2027-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10493645
• 关键词: Academic Medical Centers; Adult; Affect; American; Animal Model; Awareness; Biopsy; Biopsy Specimen; Boston; Budgets; Cardiovascular Diseases; Chronic Kidney Failure; Clinic; Clinical; Clinical Research; Collection; Communities; Consent Forms; Development; Diabetes Mellitus; Diabetic Nephropathy; Education; Employment; End stage renal failure; Endocrinologist; Endocrinology; Enrollment; Ensure; Ethics; Exclusion Criteria; Functional disorder; Geography; Glomerular Filtration Rate; Hospitals; Human; Hypertension; Individual; Infrastructure; Insulin-Dependent Diabetes Mellitus; Interdisciplinary Study; Investigation; Israel; Kidney; Kidney Diseases; Kidney Failure; Knowledge; Laboratories; Lead; Leadership; Literature; Longitudinal cohort study; Medical center; Molecular; Nephrology; Participant; Pathologic; Pathology; Patients; Phase; PhenX Toolkit; Population; Population Heterogeneity; Primary Care Physician; Primary Health Care; Proteome; Protocols documentation; Public Health; Radial; Renal function; Research; Research Personnel; Risk; Role; Safety; Science; Site; Spatial Distribution; Specialized Center; Techniques; Tissue Sample; Tissue atlas; Tissues; Vulnerable Populations; Woman; adjudication; base; clinical research site; cost; eligible participant; ethnic minority population; experience; follow-up; high risk; improved; inclusion criteria; insight; kidney biopsy; kidney cell; literacy; member; metabolome; molecular pathology; mortality; novel; novel strategies; patient engagement; patient population; precision medicine; protocol development; racial minority; recruit; retention rate; safety net; social health determinants; socioeconomic disadvantage; tertiary care; transcriptome

PROJECT SUMMARY Chronic kidney disease (CKD) affects 37 million Americans, costs tens of billions of dollars annually, and can lead to kidney failure, cardiovascular disease (CVD), and early mortality. CKD is not a single entity but rather a heterogeneous condition with a wide spectrum of underlying causes, pathologic and clinical manifestations, and varying rates of loss of kidney function. Because of the paucity of kidney biopsy samples from patients with common forms of CKD and the acknowledged limitations of animal models, our understanding of the pathology and molecular mechanisms of CKD is limited. Improved understanding of human CKD due to hypertension and diabetes will require investigation of kidney tissue from patients with CKD, using rapidly evolving techniques in molecular pathology. We are responding to RFA-DK-20-026 to continue as a multicenter CKD recruitment site for the Kidney Precision Medicine Project (KPMP) that builds upon the accomplishments of our established multidisciplinary research group in the UG3/UH3 phase. We propose to continue to participate as a successful CKD recruitment site in Boston, MA including four clinical sites: Joslin Diabetes Center, Beth Israel Deaconess Medical Center, Brigham and Women’s Hospital, and Boston Medical Center. The proposal builds upon an established infrastructure and our experience recruiting and retaining KPMP participants. In addition, our site has an outstanding safety record for participants with no major post-biopsy complications as well as exceeding the quality biospecimen metrics. For the U01 phase we propose to obtain repeat kidney biopsies in selected individuals as well as increase the focus on social determinants of health. We also will continue to biopsy individuals with longstanding Type 1 diabetes mellitus with no evidence of kidney pathology (‘resistors') to identify molecular underpinnings of protection against diabetic kidney disease. We are committed to continued collaborative protocol development, sharing best practices, and team science to achieve the KPMP’s objectives of advancing precision medicine to improve the lives of our patients with and at risk for CKD. The proposed research plan, by improving our understanding of CKD pathophysiology, has the potential to dramatically impact public health.

项目概要 慢性肾病 (CKD) 影响着 3700 万美国人，每年造成数百亿美元的损失， 导致肾衰竭、心血管疾病（CVD）和早期死亡。 CKD 不是一个单一的实体，而是一个 具有多种根本原因、病理和临床表现的异质性疾病，以及 肾功能丧失的速度不同。由于来自患有以下疾病的患者的肾活检样本很少 CKD 的常见形式和动物模型的公认局限性、我们对病理学的理解 CKD 的分子机制有限。提高对高血压引起的人类 CKD 的了解 糖尿病需要使用快速发展的技术对 CKD 患者的肾组织进行研究 分子病理学。我们正在回应 RFA-DK-20-026，以继续作为多中心 CKD 招募网站 肾脏精准医学项目 (KPMP)，该项目建立在我们既定成就的基础上 UG3/UH3阶段的多学科研究小组。我们建议作为一个成功的组织继续参与 位于马萨诸塞州波士顿的 CKD 招募中心，包括四个临床中心：乔斯林糖尿病中心、贝斯以色列女执事中心 医疗中心、布莱根妇女医院和波士顿医疗中心。该提案建立在 完善的基础设施以及我们招募和留住 KPMP 参与者的经验。此外，我们的网站 参与者拥有出色的安全记录，没有重大的活检后并发症以及超过 生物样本质量指标。对于 U01 阶段，我们建议在选定的样本中重复进行肾活检 个人以及更加关注健康的社会决定因素。我们还将继续进行活检 长期患有 1 型糖尿病且没有肾脏病理证据的个体（“抵抗者”）需要识别 预防糖尿病肾病的分子基础。我们致力于持续 协作协议开发、共享最佳实践和团队科学，以实现 KPMP 的目标 推进精准医学，以改善 CKD 患者和面临 CKD 风险的患者的生活。拟议的 研究计划通过提高我们对 CKD 病理生理学的理解，有可能产生巨大影响 公共卫生。